BGMS (Bio Green Med Solution Inc.) שולי הרווח הגולמי

Bio Green Med Solution Inc (BGMS) relies on the expertise of research scientists and a Phase I/II testing plan to bring physalicylic acid inhibitors to market. Ownership of unique patents allows Bio Green Med Solution Inc (BGMS) to establish premium pricing for its therapy, as evidenced by the gross profit margin. The value of 20.50 reflects the latest metric value, capturing the current efficiency of product cost management.
פילוחי מדדים פיננסיים ומדדי שוק עבור Bio Green Med Solution Inc (BGMS)

Gross margin determines the share of profit after deducting direct production costs, measuring the efficiency of cost management and asset pricing. An analysis of the business's gross margins allows for an assessment of the scaling potential of the kinase inhibitor portfolio of Bio Green Med Solution Inc. (BGMS), where high profitability is critical for attracting strategic pharmaceutical behemoths and securing joint funding for costly clinical trials.